secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
CIK:        0001100682
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001100682-25-000041
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Charles River Q3 revenue $1.00B (-0.5% YoY); GAAP EPS $1.10, non-GAAP $2.43
---------------------------------------------------------------------------

- Organic revenue declined 1.6%; DSA -3.1%, Manufacturing -5.1%, offset by RMS +6.5%.
- GAAP net income $54.4M ($1.10/diluted) vs $68.7M ($1.33) a year ago; non-GAAP net income $120.3M ($2.43) vs $133.7M ($2.59).
- GAAP operating margin improved to 13.3% (11.6% Q3 2024) on restructuring cost savings; non-GAAP margin dipped to 19.7% (19.9%).
- 2025 guidance narrowed: reported revenue growth (1.5%)-(0.5%) and non-GAAP EPS $10.10-$10.30, versus prior $9.90-$10.30.
- Management sees early positive signals but remains cautious; expects industry recovery to take time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100682/000110068225000041/0001100682-25-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100682/000110068225000041/crl-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001100682-25-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer